Skip to content
Back to meeting Original
iSanidad路 @isanidad 路 X路路 21 hours agoScore70

ARTEMIS-011

Body 路 original

馃К #ESMO2026 El ensayo Artemis-011 muestra que risvutatug rezetecan reduce un 67% el riesgo de progresi贸n o muerte en pacientes con osteosarcoma reca铆do o refractario, con una supervivencia libre de progresi贸n de 5,5 meses frente a 1,4 con quimioterapia
https://f.mtr.cool/lyhnh451sa

23 views 路 0 likes 路 0 reposts 路 0 replies

Source: iSanidad 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.